Evommune, Inc. (EVMN)
For informational purposes only. Not financial advice.
Evommune, Inc. (EVMN) is a publicly traded company trading at $15.37 with a market cap of 197831681. It holds a high conviction AI score of 71/100 based on fundamental, technical, and sentiment analysis.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Their pipeline includes EVO756 and EVO301, targeting conditions like chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Company Overview
Evommune, Inc. pioneers targeted therapies for chronic inflammatory diseases, leveraging its clinical-stage pipeline of EVO756 and EVO301 to address unmet needs in dermatology and gastroenterology, offering a compelling investment in innovative immunology solutions.
Investment Thesis
Evommune presents a compelling investment opportunity due to its focused pipeline targeting significant unmet needs in chronic inflammatory diseases. With EVO756 addressing CSU and AD, and EVO301 targeting AD and UC, the company has multiple potential value inflection points. The company's high gross margin of 91.8% indicates strong potential profitability upon commercialization. Upcoming clinical trial results for EVO756 and EVO301 could serve as major catalysts, driving significant stock appreciation. While the company currently operates at a loss, reflected in its negative P/E ratio of -9.26 and a profit margin of -453.2%, successful clinical development and eventual commercialization could transform these metrics. Investors should consider the inherent risks of biotechnology investments, but the potential rewards from Evommune's targeted approach and promising pipeline make it an attractive opportunity.
Key Highlights
- Market Cap of $0.22B reflects the company's current valuation and growth potential in the biotechnology sector.
- Gross Margin of 91.8% indicates strong potential profitability upon successful commercialization of its therapies.
- P/E Ratio of -9.26 reflects the company's current losses as a clinical-stage biotechnology company.
- Profit Margin of -453.2% highlights the significant R&D expenses associated with drug development.
- Focus on chronic inflammatory diseases addresses a substantial market with unmet medical needs.
Competitors
Strengths
- Focused pipeline targeting specific inflammatory diseases.
- High gross margin potential (91.8%).
- Experienced management team.
- Proprietary drug candidates with strong intellectual property protection.
Weaknesses
- Clinical-stage company with no currently approved products.
- Negative P/E ratio and profit margin, indicating current losses.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
Catalysts
- Upcoming: Clinical trial results for EVO756 in chronic spontaneous urticaria (CSU).
- Upcoming: Clinical trial results for EVO756 in atopic dermatitis (AD).
- Upcoming: Clinical trial results for EVO301 in atopic dermatitis (AD).
- Upcoming: Clinical trial results for EVO301 in ulcerative colitis (UC).
- Ongoing: Potential strategic partnerships and collaborations with larger pharmaceutical companies.
Risks
- Potential: Clinical trial failures or delays could negatively impact the company's pipeline and valuation.
- Potential: Regulatory hurdles and potential rejection of drug candidates by the FDA.
- Potential: Competition from established pharmaceutical companies with greater resources.
- Ongoing: The company's current losses and reliance on future funding to support its operations.
- Potential: Changes in healthcare policies and reimbursement rates could affect the market for its therapies.
Growth Opportunities
- Expansion of EVO756 into additional indications: EVO756, currently in development for CSU and AD, has the potential to be expanded into other inflammatory skin conditions. The global market for atopic dermatitis treatment is projected to reach $16.4 billion by 2031. Successful clinical trials and subsequent regulatory approvals for these additional indications would significantly increase EVO756's market potential and drive revenue growth for Evommune. This expansion could be pursued within the next 3-5 years following positive clinical data.
- Advancement of EVO301 in Ulcerative Colitis: EVO301, targeting both AD and UC, represents a significant growth opportunity in the gastroenterology space. The ulcerative colitis market is expected to reach $7.5 billion by 2028. Positive clinical trial results and subsequent regulatory approval for EVO301 in UC would provide Evommune with a strong foothold in this market. Clinical trials are ongoing, with potential for market entry within the next 4-6 years.
- Strategic Partnerships and Collaborations: Evommune can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline. These partnerships can provide access to additional funding, expertise, and distribution channels. Such collaborations could be initiated within the next 1-2 years, enhancing Evommune's overall growth trajectory and reducing financial risk.
- Geographic Expansion: While currently focused on the US market, Evommune has the opportunity to expand its operations into other regions, including Europe and Asia. These markets represent significant growth potential for its therapies. International expansion could begin within the next 3-5 years, following successful commercialization in the US and securing necessary regulatory approvals in other regions.
- Development of Novel Pipeline Candidates: Evommune can invest in the development of new pipeline candidates targeting other chronic inflammatory diseases. This would diversify its product portfolio and reduce reliance on its current lead programs. Investing in early-stage research and development could lead to the identification of promising new drug candidates within the next 2-3 years, setting the stage for long-term growth.
Opportunities
- Expansion of EVO756 into additional indications.
- Advancement of EVO301 in ulcerative colitis.
- Strategic partnerships and collaborations.
- Geographic expansion into new markets.
Threats
- Competition from established pharmaceutical companies.
- Clinical trial failures or delays.
- Regulatory hurdles and potential rejection of drug candidates.
- Changes in healthcare policies and reimbursement rates.
Competitive Advantages
- Proprietary drug candidates targeting specific inflammatory pathways.
- Clinical-stage pipeline with potential for significant market exclusivity upon regulatory approval.
- Expertise in developing therapies for chronic inflammatory diseases.
- Strong intellectual property protection for their drug candidates.
About
Evommune, Inc., founded in 2020 and headquartered in Palo Alto, California, is a clinical-stage biotechnology company dedicated to developing innovative therapies for chronic inflammatory diseases. The company focuses on targeting key drivers of these diseases to provide effective and targeted treatments. Evommune's approach involves rigorous scientific research and clinical development to address significant unmet medical needs. The company's lead product candidates include EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, targeting both AD and ulcerative colitis (UC). These programs represent Evommune's commitment to addressing a range of inflammatory conditions with significant patient populations. Evommune operates primarily in the United States, conducting its research and clinical trials to advance its pipeline. The company's strategy involves a combination of internal research and development efforts, as well as potential partnerships to expand its therapeutic reach. By focusing on specific inflammatory pathways, Evommune aims to create differentiated therapies that offer improved outcomes for patients suffering from chronic inflammatory diseases.
What They Do
- Develop therapies for chronic inflammatory diseases.
- Focus on key drivers of inflammatory conditions.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Target conditions such as chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).
- Advance EVO756 for the treatment of CSU and AD.
- Advance EVO301 for the treatment of AD and UC.
- Engage in research and development activities to expand their pipeline.
Business Model
- Develop and license or commercialize novel therapeutics.
- Focus on specific inflammatory pathways to create differentiated therapies.
- Generate revenue through potential partnerships and collaborations with larger pharmaceutical companies.
- Seek regulatory approvals for their drug candidates to enable commercial sales.
Industry Context
Evommune operates within the competitive biotechnology industry, focusing on chronic inflammatory diseases. This sector is characterized by high growth potential driven by increasing prevalence of autoimmune and inflammatory conditions. Key market trends include the development of targeted therapies and personalized medicine. Evommune competes with companies like ARTV (Artiva Biotherapeutics, Inc.), CDXS (Codexis, Inc.), CLYM (Clalyssa Lifesciences, Inc.), EYPT (EyePoint Pharmaceuticals, Inc.), and FTRE (Fortrea Holdings Inc.), each pursuing different approaches to treating inflammatory and immunological disorders. The overall market for inflammatory disease treatments is substantial, with significant opportunities for companies developing innovative and effective therapies.
Key Customers
- Patients suffering from chronic spontaneous urticaria (CSU).
- Patients with atopic dermatitis (AD).
- Patients diagnosed with ulcerative colitis (UC).
- Healthcare providers who prescribe treatments for these conditions.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10M | -$12M | $-0.40 |
| Q1 2025 | $3M | -$15M | $-0.48 |
Source: Company filings
Chart & Info
Price Chart
Evommune, Inc. (EVMN) stock price: $15.37 (-1.94, -11.21%)
Why Bull
- •Evommune's recent insider buying suggests those closest to the company see significant upside potential, signaling confidence in their strategy.
- •The buzz in the social trading community indicates growing excitement around Evommune's pipeline, especially their focus on inflammatory diseases.
- •Market perception seems to be shifting towards recognizing the potential of Evommune's differentiated approach in a competitive biotech landscape.
- •Positive sentiment is building around Evommune's partnerships and collaborations, suggesting validation of their technology and future growth opportunities.
Why Bear
- •Some community members express concern about the inherent risks associated with biotech companies, particularly regarding clinical trial outcomes.
- •Recent market developments suggest increased investor caution towards smaller biotech firms, potentially impacting Evommune's valuation.
- •Despite positive sentiment, there's underlying worry about competition from larger pharmaceutical companies in the inflammatory disease space.
- •A segment of the community believes the current market perception of Evommune may be overly optimistic, setting the stage for potential disappointment if expectations aren't met.
Latest News
-
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
benzinga · Feb 15, 2026
-
Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.
Investor's Business Daily · Feb 10, 2026
-
Top Midday Gainers
MT Newswires · Feb 10, 2026
-
Gold Moves Lower; CVS Health Earnings Top Views
benzinga · Feb 10, 2026
Technical Analysis
Rationale
AI-generated technical analysis for EVMN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Evommune, Inc. (EVMN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for EVMN.
Make a Prediction
Set your price target for Evommune, Inc. (EVMN), choose a timeframe, and track your prediction accuracy.
Current price: $15.37
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVMN.
Price Targets
Median: $48.00 (+223.2% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 6/100
Revenue increased 40.0% YoY, reflecting moderate but steady business growth.
-
Gross Margin 10/100
Gross margin of 91.8% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Limited cash of $16M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 10/100
Investing 917.8% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 10/100
Insiders bought +$370.44M net in recent filings, a strong confidence signal from those who know the company best.
-
Short Interest 4/100
High daily turnover of 9.78% may indicate speculative trading rather than fundamental investing.
-
Price Momentum 6/100
Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates EVMN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.
Top Midday Gainers
Gold Moves Lower; CVS Health Earnings Top Views
Frequently Asked Questions
What does Evommune, Inc. do?
Evommune, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies for chronic inflammatory diseases. The company focuses on targeting key drivers of these diseases to provide effective and targeted treatments. Their lead product candidates include EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, targeting both AD and ulcerative colitis (UC). Evommune aims to address significant unmet medical needs in dermatology and gastroenterology through rigorous scientific research and clinical development.
Is EVMN stock a good buy?
EVMN stock presents a speculative but potentially rewarding investment opportunity. The company's high gross margin potential (91.8%) suggests strong future profitability if its therapies are successfully commercialized. However, as a clinical-stage company with a negative P/E ratio (-9.26) and profit margin (-453.2%), it carries significant risk. Positive clinical trial results for EVO756 and EVO301 could serve as major catalysts, driving stock appreciation. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in EVMN.
What are the main risks for EVMN?
The main risks for Evommune include the inherent uncertainties of clinical-stage drug development. Clinical trial failures or delays could significantly impact the company's pipeline and valuation. Regulatory hurdles and potential rejection of drug candidates by the FDA also pose a risk. Additionally, Evommune faces competition from established pharmaceutical companies with greater resources. The company's current losses and reliance on future funding to support its operations further contribute to the overall risk profile.
Is EVMN a good stock to buy?
Whether EVMN is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Evommune, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.
What is the EVMN MoonshotScore?
The MoonshotScore rates EVMN from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.
How often is EVMN data updated?
EVMN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What do analysts say about EVMN?
Analyst coverage for EVMN includes consensus ratings (buy, hold, sell), 12-month price targets, and earnings estimates from major research firms. Key data points: consensus target price, number of covering analysts, recent upgrades or downgrades, and earnings beat/miss history. See the Analyst Consensus section on this page.
What are the risks of investing in EVMN?
Risk categories for EVMN include market risk, company-specific risk (management, competition), financial risk (debt, cash burn), and macroeconomic risk (rates, inflation). Beta above 1.0 indicates higher volatility than the S&P 500. Review the Risk Factors section on this page for details. All investments carry risk of loss.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and thorough research.